| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Roger A Astley | Q56773909 |
| P2093 | author name string | Phillip S Coburn | |
| Michelle C Callegan | |||
| Salai Madhumathi Parkunan | |||
| P2860 | cites work | Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection | Q26998053 |
| Role of Staphylococcus aureus Virulence Factors in Inducing Inflammation and Vascular Permeability in a Mouse Model of Bacterial Endophthalmitis | Q27305290 | ||
| Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review | Q28084070 | ||
| Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance | Q28138065 | ||
| Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors | Q28304030 | ||
| Cataract blindness--challenges for the 21st century | Q28361924 | ||
| The Streptococcus pneumoniae Capsule Is Required for Full Virulence in Pneumococcal Endophthalmitis | Q28386753 | ||
| Genomic responses in mouse models poorly mimic human inflammatory diseases | Q29547718 | ||
| Gentamicin toxicity in the primate retina | Q30461223 | ||
| Aminoglycosides: activity and resistance | Q33548221 | ||
| Toll-like receptor 2 ligand-induced protection against bacterial endophthalmitis | Q33556991 | ||
| Evidence for contribution of tripartite hemolysin BL, phosphatidylcholine-preferring phospholipase C, and collagenase to virulence of Bacillus cereus endophthalmitis | Q33599928 | ||
| New patterns of infecting organisms in late bleb-related endophthalmitis: a ten year review | Q33634243 | ||
| Immunological analysis of the aqueous humour in candida endophthalmitis. I: Experimental study | Q33646320 | ||
| Controversies in the management of open-globe injuries involving the posterior segment | Q33788729 | ||
| Role of TLR5 and flagella in bacillus intraocular infection | Q33799956 | ||
| Pathogenesis of gram-positive bacterial endophthalmitis | Q33876697 | ||
| Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model | Q33876707 | ||
| Extracellular virulence factors in Bacillus cereus endophthalmitis: methods and implication of involvement of hemolysin BL. | Q39821241 | ||
| Contribution of the pAD1-encoded cytolysin to the severity of experimental Enterococcus faecalis endophthalmitis. | Q40146952 | ||
| Controversial Points in Ocular Penicillin Therapy. | Q40644772 | ||
| An experimental model of candida endophthalmitis | Q40826997 | ||
| A comparison of pneumolysin activity and concentration in vitro and in vivo in a rabbit endophthalmitis model | Q41279007 | ||
| Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery | Q41352760 | ||
| Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy | Q41481102 | ||
| The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis | Q41541672 | ||
| Immunization with Pneumolysin Protects Against Both Retinal and Global Damage Caused byStreptococcus pneumoniaeEndophthalmitis | Q41588668 | ||
| Adhesion molecule expression in a rat model of Staphylococcus aureus endophthalmitis | Q41714072 | ||
| The NLRP3 inflammasome is active but not essential in endotoxin-induced uveitis | Q41809689 | ||
| Bacillus cereus-induced permeability of the blood-ocular barrier during experimental endophthalmitis | Q33893302 | ||
| Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions | Q33906155 | ||
| Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction | Q33987366 | ||
| TLR4 contributes to the host response to Klebsiella intraocular infection. | Q34089556 | ||
| Role of Toll-like receptor (TLR) 2 in experimental Bacillus cereus endophthalmitis | Q34097960 | ||
| Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens | Q34114172 | ||
| Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis. | Q34123551 | ||
| The Enterococcus faecalis fsrB gene, a key component of the fsr quorum-sensing system, is associated with virulence in the rabbit endophthalmitis model | Q34128168 | ||
| Contribution of membrane-damaging toxins to Bacillus endophthalmitis pathogenesis | Q34132134 | ||
| Contribution of gelatinase, serine protease, and fsr to the pathogenesis of Enterococcus faecalis endophthalmitis | Q34144716 | ||
| Experimental postoperative endophthalmitis | Q34163855 | ||
| Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis. | Q34211391 | ||
| Lysins: the arrival of pathogen-directed anti-infectives | Q34354452 | ||
| In vitro and in vivo models of Staphylococcus aureus endophthalmitis implicate specific nutrients in ocular infection | Q34395732 | ||
| Endophthalmitis caused by Enterococcus faecalis: clinical features, antibiotic sensitivities, and outcomes | Q34602379 | ||
| Relationship of plcR-regulated factors to Bacillus endophthalmitis virulence | Q35012762 | ||
| Role of wall teichoic acids in Staphylococcus aureus endophthalmitis | Q35027531 | ||
| An eleven-year retrospective study of endogenous bacterial endophthalmitis | Q35087379 | ||
| In Vivo Role of TLR2 and MyD88 Signaling in Eliciting Innate Immune Responses in Staphylococcal Endophthalmitis | Q35167160 | ||
| Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis | Q35221166 | ||
| Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study | Q35311385 | ||
| Staphylococcal accessory regulator (sar) in conjunction with agr contributes to Staphylococcus aureus virulence in endophthalmitis | Q35545994 | ||
| Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases | Q35618816 | ||
| The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies | Q35621100 | ||
| Interplay between innate and adaptive immunity in the development of non-infectious uveitis | Q35784059 | ||
| A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation | Q35895945 | ||
| Unexpected Roles for Toll-Like Receptor 4 and TRIF in Intraocular Infection with Gram-Positive Bacteria | Q36053504 | ||
| Acute endophthalmitis following cataract surgery: a systematic review of the literature | Q36121591 | ||
| Management and outcomes of postoperative endophthalmitis since the endophthalmitis vitrectomy study: the Endophthalmitis Population Study of Western Australia (EPSWA)'s fifth report | Q36142206 | ||
| The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. | Q36161698 | ||
| Blood-Retinal Barrier Compromise and Endogenous Staphylococcus aureus Endophthalmitis | Q36273810 | ||
| The comparison of fluoroquinolones to nonfluoroquinolone antibacterial agents for the prevention of endophthalmitis in a rabbit model | Q36421795 | ||
| Endophthalmitis: the latest in current management | Q36532916 | ||
| alphaB-crystallin protects retinal tissue during Staphylococcus aureus-induced endophthalmitis | Q36539622 | ||
| Role of the posterior capsule in the prevention of postoperative bacterial endophthalmitis: experimental primate studies and clinical implications | Q41900309 | ||
| Exploiting what phage have evolved to control gram-positive pathogens | Q42072037 | ||
| Efficacy of vitrectomy in improving the outcome of Bacillus cereus endophthalmitis | Q42351581 | ||
| Sustained anti-staphylococcal effect of lysostaphin in the rabbit aqueous humor | Q43064771 | ||
| Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial | Q43541201 | ||
| Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit | Q43755005 | ||
| Contribution of pneumolysin and autolysin to the pathogenesis of experimental pneumococcal endophthalmitis | Q43755085 | ||
| Immunogenic Endophthalmitis Produced in the Guinea Pig by Different Pathogenetic Mechanisms* | Q43972642 | ||
| Open globe injuries with positive intraocular cultures: factors influencing final visual acuity outcomes | Q44003908 | ||
| Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis | Q44043961 | ||
| Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. | Q44122933 | ||
| The role of vitrectomy in the treatment of postoperative bacterial endophthalmitis. An experimental study | Q44242601 | ||
| Surgery of ocular trauma; therapy of secondary intraocular infection. | Q44288802 | ||
| Bacillus endophthalmitis: roles of bacterial toxins and motility during infection | Q44364483 | ||
| Vitrectomy in endophthalmitis. Results of study using vitrectomy, intraocular antibiotics, or a combination of both | Q44367574 | ||
| Pars plana vitrectomy with or without silicone oil endotamponade in post-traumatic endophthalmitis | Q44431463 | ||
| Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis | Q44587167 | ||
| Accessory gene regulator controls Staphylococcus aureus virulence in endophthalmitis | Q44594777 | ||
| Timing of dexamethasone treatment in experimental Staphylococcus aureus endophthalmitis | Q44638993 | ||
| Intravenous treatment of experimental Staphylococcus aureus endophthalmitis: imipenem versus the combination of ceftazidime and amikacin | Q44656247 | ||
| Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). | Q44764127 | ||
| Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis | Q44777924 | ||
| Quinolone resistance among pneumococci: therapeutic and diagnostic implications | Q44883946 | ||
| Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model | Q44963900 | ||
| Failure of intravitreal dexamethasone to diminish inflammation or retinal toxicity in an experimental model of Bacillus cereus endophthalmitis | Q45182165 | ||
| Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model. | Q45271959 | ||
| Immunopathologic features of Staphylococcus epidermidis-induced endophthalmitis in the rat. | Q46119888 | ||
| Effect of intravitreal triamcinolone acetonide in the treatment of experimental Staphylococcus epidermidis endophthalmitis | Q46121000 | ||
| Incidence and outcome of endophthalmitis over a 13-year period | Q46147385 | ||
| The complement system and host defense against Pseudomonas endophthalmitis | Q46175174 | ||
| Apoptotic mechanisms within the retina in Staphylococcus epidermidis experimental endophthalmitis | Q46224694 | ||
| Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years | Q46415379 | ||
| A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model | Q46459825 | ||
| Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment | Q46481526 | ||
| Fas ligand but not complement is critical for control of experimental Staphylococcus aureus Endophthalmitis | Q46568386 | ||
| Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits | Q46808871 | ||
| Oxygen distribution in the mouse retina | Q46966312 | ||
| Quinolone resistance mechanisms in pneumococci | Q47648685 | ||
| Endophthalmitis after anti-VEGF injections | Q47679278 | ||
| The pathogenesis of acute systemic candidiasis in a susceptible inbred mouse strain | Q48267405 | ||
| Intravitreally injected human immunoglobulin attenuates the effects of Staphylococcus aureus culture supernatant in a rabbit model of toxin-mediated endophthalmitis. | Q51600722 | ||
| Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. | Q53588403 | ||
| Effect of intravitreal dexamethasone in treatment of pneumococcal endophthalmitis in rabbits. | Q54067397 | ||
| Comparative In Vitro Susceptibility of Besifloxacin and Seven Comparators Against Ciprofloxacin- and Methicillin-Susceptible/Nonsusceptible Staphylococci | Q57447485 | ||
| Penetration of amikacin into the aphakic eye | Q66878802 | ||
| The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis | Q66879851 | ||
| Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis | Q67301775 | ||
| A hemolysin-encoding plasmid contributes to bacterial virulence in experimental Enterococcus faecalis endophthalmitis | Q68091166 | ||
| Use of tobramycin in eradicating experimental bacterial endophthalmitis | Q68354648 | ||
| Infectious endophthalmitis: review of 420 cases | Q36590751 | ||
| Endophthalmitis caused by Acinetobacter baumanni: a case series | Q36685439 | ||
| Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions | Q36712635 | ||
| Toward improving therapeutic regimens for Bacillus endophthalmitis | Q36866018 | ||
| Endophthalmitis: a review of current evaluation and management | Q36875304 | ||
| Increased resistance to Staphylococcus aureus endophthalmitis in BALB/c mice: Fas ligand is required for resolution of inflammation but not for bacterial clearance | Q36911426 | ||
| A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis | Q36952770 | ||
| Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis | Q36957649 | ||
| Candida endophthalmitis: focus on current and future antifungal treatment options | Q37015976 | ||
| Ocular candidiasis: a review | Q37120095 | ||
| Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis. | Q37125014 | ||
| Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy | Q37287295 | ||
| Experimental Bacillus cereus post-traumatic endophthalmitis and treatment with ciprofloxacin | Q37322642 | ||
| Therapeutic monoclonal antibodies in ophthalmology | Q37359674 | ||
| Infectious endophthalmitis after intravitreal injection of antiangiogenic agents | Q37439275 | ||
| Intravitreal injection of therapeutic agents | Q37544116 | ||
| Pathogenicity of ocular isolates of Acinetobacter baumannii in a mouse model of bacterial endophthalmitis | Q37706631 | ||
| Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis. | Q37706964 | ||
| Antibiotics in endophthalmitis: microbiological and pharmacokinetic considerations | Q37710653 | ||
| Complications of intravitreal injections | Q37726939 | ||
| The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights | Q37732574 | ||
| Nanoparticles for retinal gene therapy | Q37746102 | ||
| Applications of nanoparticles in ophthalmology | Q37786424 | ||
| Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity | Q37839231 | ||
| Post-traumatic Infectious Endophthalmitis | Q37852347 | ||
| Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review | Q38202217 | ||
| The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. | Q38211153 | ||
| Systematic review of 342 cases of endogenous bacterial endophthalmitis. | Q38239031 | ||
| Staphylococcus aureus and its Bearing on Ophthalmic Disease | Q38672537 | ||
| Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment. | Q38678517 | ||
| Human Monocytes Engage an Alternative Inflammasome Pathway | Q38781456 | ||
| Traumatic endophthalmitis | Q39655609 | ||
| Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology | Q39685606 | ||
| Differential bacterial gene expression during experimental pneumococcal endophthalmitis | Q39734668 | ||
| Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin | Q68795016 | ||
| Comparative treatment of experimental Staphylococcus epidermidis endophthalmitis | Q68808595 | ||
| Experimental Bacterial Endophthalmitis | Q69378322 | ||
| A schematic eye for the mouse, and comparisons with the rat | Q70080416 | ||
| Postoperative Propionibacterium endophthalmitis. Treatment strategies and long-term results | Q70674491 | ||
| Posttraumatic endophthalmitis | Q71289913 | ||
| The endophthalmitis vitrectomy study | Q71559448 | ||
| The effect of trauma on the ocular penetration of intravenous ciprofloxacin | Q71760753 | ||
| Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus | Q72106777 | ||
| Complement system and host defense against staphylococcal endophthalmitis | Q72287054 | ||
| Evaluation of therapeutic measures for treating endophthalmitis caused by isogenic toxin-producing and toxin-nonproducing Enterococcus faecalis strains | Q72410757 | ||
| Aminoglycoside toxicity in the treatment of endophthalmitis. The Aminoglycoside Toxicity Study Group | Q72718712 | ||
| Penetration of topical and oral ofloxacin into the aqueous and vitreous humor of inflamed rabbit eyes | Q73022416 | ||
| Intravenous gentamicin and ceftazidime in penetrating ocular trauma: a swine model | Q73113300 | ||
| Experimental pseudomonal posttraumatic endophthalmitis in a swine model. Treatment with ceftazidime, amikacin, and imipenem | Q73322982 | ||
| Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone | Q73467417 | ||
| Mitigation of neutrophil infiltration in a rat model of early Staphylococcus aureus endophthalmitis | Q73568688 | ||
| Implication of pneumolysin as a virulence factor in Streptococcus pneumoniae endophthalmitis | Q74035169 | ||
| Posttraumatic endophthalmitis | Q77334704 | ||
| Penetration of topical and oral ciprofloxacin into the aqueous and vitreous humor in inflamed eyes | Q77915750 | ||
| Intravitreal dexamethasone effect on intravitreal vancomycin elimination in endophthalmitis | Q78129743 | ||
| Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis | Q78257582 | ||
| Study of experimental intraocular infection. I. The recoverability of organisms inoculated into ocular tissues and fluids. II. The influence of antibiotics and cortisone, alone and combined, on intraocular growth of these organisms | Q78716296 | ||
| Role of swarming migration in the pathogenesis of bacillus endophthalmitis | Q79143819 | ||
| Toll-like receptor signalling pathways as key targets for mediating the anti-inflammatory and immunosuppressive effects of glucocorticoids | Q79246146 | ||
| Acute inflammation and loss of retinal architecture and function during experimental Bacillus endophthalmitis | Q79369986 | ||
| Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series | Q79447402 | ||
| Histopathological study on experimental endophthalmitis induced by bloodstream infection with Candida albicans | Q79808432 | ||
| Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis | Q80204645 | ||
| Bleb-associated endophthalmitis: clinical characteristics and visual outcomes | Q80407452 | ||
| Endogenous endophthalmitis: microorganisms, disposition and prognosis | Q80858831 | ||
| Ten years after... are findings of the Endophthalmitis Vitrectomy Study still relevant today? | Q81149276 | ||
| Intraocular penetration of streptomycin following systemic and local administration | Q82117065 | ||
| Intravitreal penetration of penicillin and penicillin therapy of infections of the vitreous | Q82192291 | ||
| The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis | Q82795647 | ||
| Expression of TNF-alpha, IL-1beta, and IFN-gamma in Staphylococcus epidermidis slime-positive experimental endophthalmitis is closely related to clinical inflammatory scores | Q82862160 | ||
| In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates | Q83137096 | ||
| Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials | Q83219194 | ||
| Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial | Q83355913 | ||
| Evaluation of Pseudomonas aeruginosa staphylolysin (LasA protease) in the treatment of methicillin-resistant Staphylococcus aureus endophthalmitis in a rat model | Q83464516 | ||
| Successful treatment of endogenous Klebsiella pneumoniae endophthalmitis: a case report | Q84596828 | ||
| Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics | Q84628588 | ||
| Treatment of experimental Bacillus cereus endophthalmitis using intravitreal moxifloxacin with or without dexamethasone | Q84746801 | ||
| Evolving fluoroquinolone resistance among coagulase-negative Staphylococcus isolates causing endophthalmitis | Q85643464 | ||
| P304 | page(s) | 30-48 | |
| P577 | publication date | 2016-05-03 | |
| P1433 | published in | Progress in Retinal and Eye Research | Q15760062 |
| P1476 | title | Modeling intraocular bacterial infections | |
| P478 | volume | 54 |
| Q46189476 | A Novel Biomimetic Nanosponge Protects the Retina from the Enterococcus faecalis Cytolysin |
| Q93081876 | An Eye on Staphylococcus aureus Toxins: Roles in Ocular Damage and Inflammation |
| Q89965825 | Bacillus S-Layer-Mediated Innate Interactions During Endophthalmitis |
| Q50094345 | Culture-Positive Endogenous Endophthalmitis: An Eleven-Year Retrospective Study in the Central Region of Thailand |
| Q64054784 | Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections |
| Q30238724 | From Immunologically Archaic to Neoteric Glycovaccines |
| Q38689789 | Intraocular Cytokine Levels in Post-Cataract Endophthalmitis and their Association with Visual Outcome |
| Q92988178 | Pathobiology of Aspergillus Fumigatus Endophthalmitis in Immunocompetent and Immunocompromised Mice |
| Q92321163 | Rapid pathogen identification and antimicrobial susceptibility testing in in vitro endophthalmitis with matrix assisted laser desorption-ionization Time-of-Flight Mass Spectrometry and VITEK 2 without prior culture |
| Q93072052 | S-layer Impacts the Virulence of Bacillus in Endophthalmitis |
| Q89595741 | The cereus matter of Bacillus endophthalmitis |
| Q40280902 | The role of pili in Bacillus cereus intraocular infection |
Search more.